South San Francisco, CA — June 7, 2018 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with…Original Article
FDA Approves Genentech’s Rituxan (rituximab) for Pemphigus Vulgaris
